On November 30, 2018, The Dow Chemical Company (the “Company”) completed the sale and issuance (the “Offering”) of $2.0 billion in aggregate principal amount of notes consisting of $500,000,000 principal amount of 4.550% Notes due 2025 (the “Notes due 2025”), $600,000,000 principal amount of 4.800% Notes due 2028 (the “Notes due 2028”) and $900,000,000 principal amount of 5.550% Notes due 2048 (the “Notes due 2048,” and together with the Notes due 2025 and the Notes due 2028, the “Notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”) and outside the United States tonon-U.S. persons in reliance on Regulation S under the Securities Act. The Offering was made pursuant to a Purchase Agreement (the “Purchase Agreement”), dated as of November 28, 2018, among the Company and the representatives of the initial purchasers named therein.
The Notes were issued under an Indenture dated as of May 1, 2008 (the “Indenture”), between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee (the “Trustee”), as supplemented by the First Supplemental Indenture, dated as of November 30, 2018 (the “First Supplemental Indenture”), among the Company, Dow Holdings Inc. and the Trustee. The Notes are the senior unsecured obligations of the Company.
The First Supplemental Indenture and the forms of the Notes due 2025, the Notes due 2028 and the Notes due 2048 are attached as Exhibits 4.1, 4.2, 4.3 and 4.4, respectively, to this Current Report on Form8-K (the “Report”) and are incorporated by reference into this Report.
Registration Rights Agreement
The holders of the Notes are entitled to the benefits of a Registration Rights Agreement, dated as of November 30, 2018 (the “Registration Rights Agreement”), between the Company and the representatives of the initial purchasers under the Purchase Agreement. Pursuant to the Registration Rights Agreement, the Company has agreed to file a registration statement with the Securities and Exchange Commission for an offer to exchange the Notes for a new issuance of substantially identical notes issued under the Securities Act (the “Exchange Offer”) and to cause the Exchange Offer to be consummated within 365 days after November 30, 2018. The Company may be required to provide a shelf registration statement to cover resales of the Notes under certain circumstances. If the Company fails to satisfy its obligations under the Registration Rights Agreement, it may be required to pay additional interest on the Notes.
The Registration Rights Agreement is attached as Exhibit 4.5 to this Report and is incorporated by reference into this Report. The foregoing description of the Registration Rights Agreement does not purport to be complete and is qualified in its entirety by reference to such Exhibit.
Item 9.01 | Financial Statements and Exhibits |
(d) Exhibits